BioSpace News Archive

Demonstrating its commitment to advancing the next generation of palliative care leaders and ensuring people with serious illness and their caregivers live well

Teva Announces Launch of a Generic Version of NuvaRing ® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States

The American College of Emergency Physicians applauds the U.S. Department of Health and Human Services’ decision to effectively remove the “X-waiver” requirement for physicians, expanding their ability to utilize medication-assisted treatment for patients struggling with opioid use disorder.

Adastra Pharmaceuticals Inc. (Adastra), a biopharmaceutical company focused on the development of first-in-class therapeutics for the treatment of cancer, today announced that Scott Megaffin , Chief Executive Officer, will present at the inaugural 2021 B . Riley Securities’ Oncology Investor Conference, being held virtually Jan

Frontage Laboratories and Frontage Clinical Services are pleased to announce plans to provide full service human radiolabeled Absorption, Metabolism, and Excretion study capabilities, subject to receipt of required regulatory approvals.

Cognate BioServices, Inc., the premier commercial-ready, global CDMO in the Cell and Gene Therapy industry, announced today its plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and increase office support at its facilities in the United States and Europe .

Sema4, a patient-centered health intelligence company, today announced the appointment of William K. Oh, M.D., to the newly established senior leadership position of Chief Medical Science Officer

La Jolla, California--(Newsfile Corp. - January 14, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) (“Tryp” or the “Company”), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce the appointment of Gregory M. McKee to the Company’s board of directors.

Saskatoon, Saskatchewan--(Newsfile Corp. - January 14, 2021) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce that it has received over C$1.5 million from the exercise of approximately 3.2 million common share purchase warrants at an average weighted exercise price of C$0.48 per share.

According to Global Market Insights, Inc., analysis report, global implantable medical devices market is estimated to surpass US$138.5 billion by 2025. Described below are some factors driving industry trends.